

Final results 2014/15

Andrew Williams – Chief Executive
Kevin Thompson – Finance Director

Summary 2014/15

**Strong
growth &
returns**

Revenue
+7%
£726m

Profit
+10%
£153.6m

ROS
21.2%
(LY: 20.7%)

**Continued
strategic
investment**

ROW revenue
+16%
£197m

R&D spend
+8%
£35m

Acquisitions
£84m
spend

**Good cash
performance**

Cash flow
87%
of adjusted profit



ROTIC
16.3%
(LY: 16.7%*)

Dividend
+7%
11.96p

- Prior year restated

Financial Review

Record results



* Profit before amortisation of acquired intangibles, acquisition items, profit or loss on disposal of operations and curtailment gain on DB pension schemes (2013/14 only)

Revenue growth

FY 2014/15

	% growth
➤ Headline growth	7%
➤ Disposal	1%
➤ Currency	<u>2%</u>
➤ Ongoing at Constant currency	10%
➤ Acquisitions	<u>(5%)</u>
➤ Organic constant currency growth	5%


Revenue growth

FY 2014/15

	£m	Total	Organic: Constant Currency
H1	341	2%	4%
H2	385	12%	6%
Total	726	7%	5%


Revenue by destination

Revenue and revenue growth, 2014/15



Revenue by destination: organic constant currency

Revenue and revenue growth, 2014/15



Profit* growth

FY 2014/15

	% growth
➤ Headline growth	10%
➤ Currency	<u>2%</u>
➤ Ongoing at Constant currency	12%
➤ Acquisitions	<u>(5%)</u>
➤ Organic constant currency growth	7%

* Profit before amortisation of acquired intangibles, acquisition items, profit or loss on disposal of operations and curtailment gain on DB pension schemes (2013/14 only)

Profit* growth

	£m	Total	Organic: Constant Currency
H1	69.0	6%	7%
H2	84.6	13%	7%
Total	153.6	10%	7%

* Profit before amortisation of acquired intangibles, acquisition items, profit or loss on disposal of operations and curtailment gain on DB pension schemes (2013/14 only)

Currency

- Translation impact in 14/15
 - H1 net adverse impact 5%
 - Full year net adverse impact 2%
- At current Fx rates 15/16 impact*:-
 - H1: ~2% Benefit
 - FY: ~ 1% Benefit
 - Impact varying by sector
- More information in Appendix

* Based on 14/15 results


Cash flow 2014/15

Working capital:

outflow £6m (2014: £11m)

Effective tax rate: 23.2% (2014:23.3%)

Pensions: Deficit £67m (2014: £37m)



Acquisitions:
£84m spend
plus £4m earn-outs

Dividend:
7% increase

Debt:
£100.9m net debt (2014: £74.5m net debt)

Funding

- £360m facility – 5 years to November 2018
- Comfortable with net debt of up to 1.25x EBITDA (March 15: 0.57x)
- Strong balance sheet with significant capacity



Financial KPI Summary 2014/15

	<u>Target</u>	<u>Achieved</u>
Organic profit growth*	> 5%	7%
Organic revenue growth*	> 5%	5%
Revenue outside UK/Europe/USA	30% by 2015	27%
Return on Sales	> 18%	21.2%
Returns on Total Invested Capital	>12%	16.3%
R&D investment (% of revenue)	> 4%	4.8%
Cash conversion	> 85%	87%

* at constant currency



Trading Review

Sector performances





- Profit before amortisation of acquired intangible assets, acquisition items and profit or loss on disposal of operations

Sector performances: Organic constant currency growth



- Profit before amortisation of acquired intangible assets, acquisition items and profit or loss on disposal of operations


Process Safety: Trading performance



Return on Sales: 28.3%


Process Safety: Revenue by destination

FY 2014/15: % of sector & % growth



Process Safety: Revenue by end market


% of sector



Infrastructure Safety: Trading performance


Revenue: +6%

Organic ccy: +5%



Profit: +12%


Organic ccy: +12%



Return on Sales: 21.4%


Infrastructure Safety: Revenue by destination

FY 2014/15: % of sector & % growth [excluding disposal]





Infrastructure Safety: Revenue by end market

% of sector




Medical: Trading performance



Return on Sales: 26.8%


Medical: Revenue by destination

FY 2014/15: % of sector & % growth





Medical: Revenue by end market

% of sector




Environmental & Analysis: Trading performance



Return on Sales: 16.7%


Environmental & Analysis: Revenue by destination

FY 2014/15: % of sector & % growth



Environmental & Analysis: Revenue by end market

% of sector



Strategy update

- Innovation
- International Expansion
- Talent Development
- M&A


Innovation: HITE Film



The HITE 2015 video can be viewed on the Halma website at: <http://www.halma.com/news/video/corporate-videos.aspx>

International expansion: China R&D

Sales to China




Ocean Optics Accuman PR-500




SunTech BP60

Talent Development: sector structures



Acquisitions: past 10 years



Summary and Outlook statement

“..... through continued and disciplined execution of our well proven growth strategy. We expect to make further progress in the year ahead”

Questions

Appendices

Currency impacts

	\$		% change	€		% change
	14/15	13/14		14/15	13/14	
• Average rates v £	1.61	1.59	(1%)	1.27	1.19	(7%)
• <u>1% change*</u>			\$ (~40% of total)			€ (~15% of total)
Revenue			+/- £2.9m			+/- £0.9m
Profit			+/- £0.6m			+/- £0.2m
• At \$1.55/€1.40 average rates full year profit would increase by a net amount of approximately £1m (<1%), and revenue by approximately £5m (<1%)*. Infrastructure Safety ~1% adverse impact. Process Safety ~1%, Medical and Environmental & Analysis 1-2% positive impact.						
• At \$1.55/€1.40 average rates half year profit and revenue 2% positive impact.*						

* Based on 2014/15 results

Profit Adjustments*

	2014/15 £m	2013/14 £m
Amortisation of Intangibles	(19.9)	(17.5)
Acquisitions items**	(1.5)	12.5
Disposal of operations	1.4	(0.5)
Defined Benefit pension schemes closure	-	3.9
	(20.0)	(1.6)

* Items (charged)/credited in arriving at Statutory profit

** Including adjustment to acquisition contingent consideration

Pensions

DB plans Deficit	March 15	March 14
	£m	£m
Assets	224.8	190.5
Liabilities	(291.6)	(227.3)
Deficit	(66.8)	(36.8)

- Discount rate reduced to 3.25% (March 2014: 4.4%) significantly increasing liabilities.
- Closed DB to future accrual December 2014
- Contributions to pay off deficit : currently £7m/year (subject to outcome of 2014 triennial valuation)
- IAS 19 (Revised) adopted in 2013/14.

Acquisitions/Disposals

	Sector	Consideration				
		Acquired	Initial £m	Maximum Earn out £m	Revenue* £m	EBIT* £m
2014/15 Acquisitions						
Plasticspritzerei	Medical	May 14	4	-	-	0.7
Advanced Electronics	Infrastructure Safety	May 14	14	10	14.6	2.5
RCS	Process Safety	May 14	64	-	26.6	6.6
			<u>82</u>	<u>10</u>		
2015/16 Acquisitions						
VAS	Medical	May 15	3	1	1.5	0.3
			<u>3</u>	<u>1</u>		
2014/15 Disposal						
		Disposal	Proceeds			
Monitor	Infrastructure Safety	May 14	4	-	7.5	~1.0

* At acquisition/disposal run-rate

Impact of M&A

Revenue £m*

		Actual 14/15	Expected Contribution 15/16
Acquisitions	14/15	35	6
Disposal	14/15	(6)	(1)
Acquisition	15/16	-	1
		29	6

Profit after financing costs £m*

		Actual 14/15	Expected Contribution 15/16
Acquisitions	14/15	7.4	1.3
Disposal	14/15	(1.0)	-
Acquisition	15/16	-	0.2
		6.4	1.5

* at acquisition/disposal run-rate

2014/15 Full year

	Notes	Full year 15/16 forecasts	14/15 Actual
Capex	1	~ £27.5m	£23.2m
Effective tax rate	2	~ 23.0%	23.2%
Central costs	3	~ £10.8m	£9.0m
Net finance expense	4	~ £5.2m	£4.9m

Notes:

1. 14/15 capex includes £5m for a new property purchase. 15/16 includes a further £5m.
2. 15/16 forecast includes further 1% fall in UK CT rate and expected mix of profits.
3. HITE event in 2015/16 plus further investment in Talent and emerging markets.
4. Based on forecast including May 2015 acquisition. Assumed 0.5% interest rate increase in H2.

Sector history

£m		10/11	11/12	12/13**	13/14	14/15
Sector revenue	Process Safety	103.0	122.2	125.7	126.7	158.4
	Infrastructure Safety	197.2	204.3	205.3	220.3	234.1
	Medical	82.2	100.4	136.1	163.2	169.3
	Environmental & Analysis	136.2	153.4	152.4	166.5	164.4
	Inter-segmental sales	(0.2)	(0.4)	(0.3)	(0.2)	(0.1)
	Group revenue	518.4	579.9	619.2	676.5	726.1
Sector profit*	Process Safety	24.5	29.2	32.3	34.9	44.8
	Infrastructure Safety	39.0	39.1	41.5	44.4	50.0
	Medical	20.4	26.3	35.9	41.8	45.4
	Environmental & Analysis	25.7	31.6	30.4	31.8	27.4
	Segment Profit	109.6	126.2	140.1	152.9	167.6
	Central cost/net finance expense	(5.0)	(5.7)	(11.6)	(12.7)	(14.0)
Profit*		104.6	120.5	128.5	140.2	153.6

* Profit before amortisation of acquired intangibles, acquisition items, profit or loss on disposal of operations and curtailment gain on DB pension schemes (2013/14 only)

** 12/13 profit Restated for IAS 19 accounting for pensions. Earlier periods have not been restated.

Disclaimer

This document contains statements about Halma plc that are or may be forward-looking statements. Forward-looking statements include statements relating to (i) future capital expenditures, expenses, revenues, earnings, synergies, economic performance, indebtedness, financial condition, dividend policy, losses and future prospects; (ii) business and management strategies and the expansion and growth of Halma plc's operations; and (iii) the effects of government regulation on business.

These forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of Halma plc. They involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any results, performance or achievements expressed or implied by such statements. They are based on numerous assumptions regarding the present and future business strategies and the future operating environment. All subsequent oral or written forward-looking statements attributable to Halma plc or any of its shareholders or any persons acting on its behalf are expressly qualified in their entirety by this cautionary statement. All forward-looking statements included in this document speak only as of the date they were made and are based on information then available to Halma plc. Investors should not place undue reliance on such forward-looking statements, and Halma plc does not undertake any obligation to update publicly or revise any forward-looking statements.

No representation or warranty, express or implied, is given regarding the accuracy of the information or opinions contained in this document and no liability is accepted by Halma plc or any of its directors, members, officers, employees, agents or advisers for any such information or opinions.

This information is being supplied to you for information purposes only and not for any other purpose. This document and the information contained in it does not constitute or form any part of an offer of, or invitation or inducement to apply for, securities.

The distribution of this document in jurisdictions other than the United Kingdom may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of laws of any such other jurisdiction.